Reginald Gohh is a Nephrology physician. OpenAlex indexes 138 publications with 2,501 citations (h-index 30); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
375 Wampanoag Trl
Suite 302a
Riverside, RI 029152232
Telephone
401-649-4060Registry record last updated 8 Feb 2019.
Clinical trials
- Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients
Sponsor: Rhode Island Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20251 payment
- Amneal Pharmaceuticals LLCProgram year20251 payment
- Hikma Pharmaceuticals USAProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
39.4%Beta blocker13.9%Carvedilol35%Metoprolol Succinate33%Metoprolol Tartrate21%Labetalol Hcl11%Part D<11 patientsCalcium channel blocker7.8%Amlodipine Besylate65%Nifedipine Er35%Part D≥18 patients+ 6 more classes in this area
Metabolism & gastrointestinal
38.6%Corticosteroid21.4%Prednisone100%Part D≥63 patientsProton pump inhibitor6.5%Pantoprazole Sodium81%Omeprazole19%Part D<11 patients+ 4 more classes in this area
Anti-infectives
5.1%Short-acting sulfonamides5.1%Sulfamethoxazole-Trimethoprim100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Posoleucel in Kidney Transplant Recipients with BK Viremia
Journal of the American Society of Nephrology
2024 - Genetic evaluation of living kidney donor candidates: A review and recommendations for best practices
American Journal of Transplantation
2023 - Successful recovery from COVID‐19 in three kidney transplant recipients who received convalescent plasma therapy
Transplant Infectious Disease
2020 - A single‐center analysis of early readmission after renal transplantation
Clinical Transplantation
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”